Pershing Edward 4

What Happened

• Edward Pershing, CEO and director of Provectus Biopharmaceuticals, reported an acquisition-type transaction on 2026-01-28: a grant/award of a derivative security. The Form 4 lists N/A shares at $0.00 (no immediate common shares purchased or sold and no dollar value reported).
• The filing reflects conversion rights tied to an 8% unsecured convertible promissory note issued in the Issuer’s 2025 financing, not an open-market buy or sale.

Key Details

• Transaction date: 2026-01-28; Form 4 filed 2026-01-29 (filed within standard SEC timing).
• Reported transaction: Grant/award of a derivative security (entry shows N/A shares; $0.00 per share).
• Shares owned after transaction: Not specified on the reported line (N/A).
• Footnotes of note:
  • F1: The Reporting Person may elect to convert outstanding principal and interest of the 8% convertible note into Series D‑1 Convertible Preferred Stock at $2.862 per share; the note will automatically convert into Series D‑1 at 12 months after the note’s issue date.
  • F2: Each Series D‑1 preferred is convertible into 10 shares of common stock; Series D‑1 will automatically convert into common on June 26, 2026 unless earlier converted.
• Issuance context: The note was issued pursuant to Provectus’s 2025 financing.

Context

• This filing documents a derivative/award related to a convertible note. It does not show an immediate purchase or sale of common stock and therefore does not directly indicate buying or selling sentiment in the common shares.
• If converted, the preferred/common conversion mechanics (preferred converts 10:1 into common and conversion price $2.862 for the preferred) could affect outstanding common shares; the actual number and value depend on the note principal/interest amount and whether/when conversion occurs.